Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
November 2019
Volume 18, Issue 11
Volume 18, Issue 11
Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance
Jump to section
- Article
- Abstract
- Rationale for Inhibiting EGFR in SCCHN
- The Limitations of Anti-EGFR Targeting in SCCHN
- Resistance Mechanisms to EGFR Inhibition
- Emergence of Immunotherapy as an Effective Therapeutic Modality in SCCHN
- Immune Implications of EGFR Targeting
- Forging the Alliance
- Disclosure of Potential Conflicts of Interest
- Acknowledgments
- Footnotes
- References
- Figures & Data
- Info & Metrics
Advertisement